Assess disease activity in lupus
The SLEDAI was originally developed to determine disease activity in patients with lupus.
SLEDAI-2K was developed as a modification of SLEDAI in order to include persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences. Specifically SLEDAI-2K allows persistent active disease in alopecia, mucous membrane ulcers, rash, and proteinuria to be scored.
SLEDAI-2K was validated against the original SLEDAI as a predictor for mortality and as a measure of global disease activity. It was also found to be equivalent to SLEDAI in describing changes in disease activity from one visit to the next.
Gladman DD, Ibañez D, Urowitz MB.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.